Feb 283 min readPBG BioPharma Inc. Announces the launch of a Phase 2/3 Clinical Trial on its Cannabinoid-based Drug Product ProZ-001 as an Adjunctive Therapy for Acute Bipolar Depression
Feb 13, 20232 min readPBG BioPharma Inc. Successfully Files Cannabinoid Master Drug File to Health Canada
Sep 12, 20223 min readPBG BioPharma Inc. Announces Launch of GenBioChem® Line of Natural Health Products
